139 related articles for article (PubMed ID: 24297701)
1. BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
Buffa P; Romano C; Pandini A; Massimino M; Tirrò E; Di Raimondo F; Manzella L; Fraternali F; Vigneri PG
FASEB J; 2014 Mar; 28(3):1221-36. PubMed ID: 24297701
[TBL] [Abstract][Full Text] [Related]
2. How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
Zhang H; He X; Ni D; Mou L; Chen X; Lu S
J Biomol Struct Dyn; 2020 Jan; 38(1):89-100. PubMed ID: 30661457
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.
Tanneeru K; Guruprasad L
PLoS One; 2013; 8(11):e78556. PubMed ID: 24236021
[TBL] [Abstract][Full Text] [Related]
4. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
[TBL] [Abstract][Full Text] [Related]
5. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
8. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
[TBL] [Abstract][Full Text] [Related]
9. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
10. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
11. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
Melge AR; Kumar LG; K P; Nair SV; K M; C GM
J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
[TBL] [Abstract][Full Text] [Related]
12. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
O'Hare T; Zabriskie MS; Eide CA; Agarwal A; Adrian LT; You H; Corbin AS; Yang F; Press RD; Rivera VM; Toplin J; Wong S; Deininger MW; Druker BJ
Blood; 2011 Nov; 118(19):5250-4. PubMed ID: 21908430
[TBL] [Abstract][Full Text] [Related]
13. Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS.
Damaraju VL; Weber D; Kuzma M; Cass CE; Sawyer MB
J Biol Chem; 2016 Sep; 291(36):18809-17. PubMed ID: 27432881
[TBL] [Abstract][Full Text] [Related]
14. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells.
Kato Y; Kunimasa K; Sugimoto Y; Tomida A
Biochem Biophys Res Commun; 2018 Oct; 504(4):721-726. PubMed ID: 30217442
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
17. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.
Miller GD; Woessner DW; Sirch MJ; Lim CS
Mol Pharm; 2013 Sep; 10(9):3475-83. PubMed ID: 23915432
[TBL] [Abstract][Full Text] [Related]
18. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
O'Hare T; Deininger MW; Eide CA; Clackson T; Druker BJ
Clin Cancer Res; 2011 Jan; 17(2):212-21. PubMed ID: 21098337
[TBL] [Abstract][Full Text] [Related]
19. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
20. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
